Exact Mass: 459.2383
Exact Mass Matches: 459.2383
Found 500 metabolites which its exact mass value is equals to given mass value 459.2383
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cerivastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites
Apstatin
2,5-Dihydroxy-1-octadec-9-enoyloxypyrrole-3-sulfonic acid
SEERZIQQUAZTOL-WOJBJXKFSA-N
Panax ginseng Tetrapeptide
Constituent of Panax ginseng (ginseng). Panax ginseng Tetrapeptide is found in tea.
Trifarotene
D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AD - Retinoids for topical use in acne C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D003879 - Dermatologic Agents
cyclo(-Phe-Gly-Ala1-Leu-Ala2-)|cyclo(L-alanyl-L-leucyl-L-alanyL-glycyl-L-phenylalanyl)|cyclozanthoxylane A
Ile Asn Val Asp
Asp Val Ala Arg
Ala Ala Ile Trp
Ala Ala Leu Trp
Ala Ala Trp Ile
Ala Ala Trp Leu
Ala Asp Arg Val
Ala Asp Val Arg
Ala Glu Ile Gln
Ala Glu Leu Gln
Ala Glu Gln Ile
Ala Glu Gln Leu
Ala Ile Ala Trp
Ala Ile Glu Gln
Ala Ile Gln Glu
Ala Ile Trp Ala
Ala Lys Asn Gln
Ala Lys Gln Asn
Ala Leu Ala Trp
Ala Leu Glu Gln
Ala Leu Gln Glu
Ala Leu Trp Ala
Ala Asn Lys Gln
Ala Asn Gln Lys
Ala Gln Glu Ile
Ala Gln Glu Leu
Ala Gln Ile Glu
Ala Gln Lys Asn
Ala Gln Leu Glu
Ala Gln Asn Lys
Ala Arg Asp Val
Ala Arg Val Asp
Ala Val Asp Arg
Ala Val Arg Asp
Ala Trp Ala Ile
Ala Trp Ala Leu
Ala Trp Ile Ala
Ala Trp Leu Ala
Cys Lys Leu Pro
Cys Lys Pro Ile
Cys Lys Pro Leu
Cys Leu Lys Pro
Cys Leu Pro Lys
Cys Pro Lys Ile
Asp Ala Arg Val
Asp Ala Val Arg
Asp Gly Ile Arg
Asp Gly Leu Arg
Asp Gly Arg Ile
Asp Gly Arg Leu
Asp Ile Gly Arg
Asp Ile Asn Val
Asp Ile Arg Gly
Asp Ile Val Asn
Asp Lys Pro Thr
Asp Lys Thr Pro
Asp Leu Gly Arg
Asp Leu Asn Val
Asp Leu Arg Gly
Asp Leu Val Asn
Asp Asn Ile Val
Asp Asn Leu Val
Asp Asn Val Ile
Asp Asn Val Leu
Asp Pro Lys Thr
Asp Pro Thr Lys
Asp Gln Val Val
Asp Arg Ala Val
Asp Arg Gly Ile
Asp Arg Gly Leu
Asp Arg Ile Gly
Asp Arg Leu Gly
Asp Arg Val Ala
Asp Thr Lys Pro
Asp Thr Pro Lys
Asp Val Ile Asn
Asp Val Leu Asn
Asp Val Asn Ile
Asp Val Asn Leu
Asp Val Gln Val
Asp Val Arg Ala
Asp Val Val Gln
Glu Ala Ile Gln
Glu Ala Leu Gln
Glu Ala Gln Ile
Glu Ala Gln Leu
Glu Gly Arg Val
Glu Gly Val Arg
Glu Ile Ala Gln
Glu Ile Gln Ala
Glu Lys Pro Ser
Glu Lys Ser Pro
Glu Leu Ala Gln
Glu Leu Gln Ala
Glu Asn Val Val
Glu Pro Lys Ser
Glu Pro Ser Lys
Glu Gln Ala Ile
Glu Gln Ala Leu
Glu Gln Ile Ala
Glu Gln Leu Ala
Glu Arg Gly Val
Glu Arg Val Gly
Glu Ser Lys Pro
Glu Ser Pro Lys
Glu Val Gly Arg
Glu Val Asn Val
Glu Val Arg Gly
Glu Val Val Asn
Gly Asp Ile Arg
Gly Asp Leu Arg
Gly Asp Arg Ile
Gly Asp Arg Leu
Gly Glu Arg Val
Gly Glu Val Arg
Gly Ile Asp Arg
Gly Ile Arg Asp
Gly Lys Gln Gln
Gly Leu Asp Arg
Gly Leu Arg Asp
Gly Met Pro Arg
Gly Met Arg Pro
Gly Pro Met Arg
Gly Pro Arg Met
Gly Gln Lys Gln
Gly Gln Gln Lys
Gly Arg Asp Ile
Gly Arg Asp Leu
Gly Arg Glu Val
Gly Arg Ile Asp
Gly Arg Leu Asp
Gly Arg Met Pro
Gly Arg Pro Met
Gly Arg Val Glu
Gly Val Glu Arg
Gly Val Arg Glu
Gly Val Val Trp
Gly Val Trp Val
Gly Trp Val Val
Ile Ala Ala Trp
Ile Ala Glu Gln
Ile Ala Gln Glu
Ile Ala Trp Ala
Ile Asp Gly Arg
Ile Asp Asn Val
Ile Asp Arg Gly
Ile Asp Val Asn
Ile Glu Ala Gln
Ile Glu Gln Ala
Ile Gly Asp Arg
Ile Gly Arg Asp
Ile Asn Asp Val
Ile Gln Ala Glu
Ile Gln Glu Ala
Ile Arg Asp Gly
Ile Arg Gly Asp
Ile Val Asp Asn
Ile Val Asn Asp
Ile Trp Ala Ala
Lys Ala Asn Gln
Lys Ala Gln Asn
Lys Asp Pro Thr
Lys Asp Thr Pro
Lys Glu Pro Ser
Lys Glu Ser Pro
Lys Gly Gln Gln
Lys Leu Pro Cys
Lys Asn Ala Gln
Lys Asn Gln Ala
Lys Pro Asp Thr
Lys Pro Glu Ser
Lys Pro Ser Glu
Lys Pro Thr Asp
Lys Gln Ala Asn
Lys Gln Gly Gln
Lys Gln Asn Ala
Lys Gln Gln Gly
Lys Ser Glu Pro
Lys Ser Pro Glu
Lys Thr Asp Pro
Lys Thr Pro Asp
Leu Ala Ala Trp
Leu Ala Glu Gln
Leu Ala Gln Glu
Leu Ala Trp Ala
Leu Asp Gly Arg
Leu Asp Asn Val
Leu Asp Arg Gly
Leu Asp Val Asn
Leu Glu Ala Gln
Leu Glu Gln Ala
Leu Gly Asp Arg
Leu Gly Arg Asp
Leu Asn Asp Val
Leu Asn Val Asp
Leu Gln Ala Glu
Leu Gln Glu Ala
Leu Arg Asp Gly
Leu Arg Gly Asp
Leu Val Asp Asn
Leu Val Asn Asp
Leu Trp Ala Ala
Met Gly Pro Arg
Met Gly Arg Pro
Met Pro Gly Arg
Met Pro Arg Gly
Met Arg Gly Pro
Met Arg Pro Gly
Asn Ala Lys Gln
Asn Ala Gln Lys
Asn Asp Ile Val
Asn Asp Leu Val
Asn Asp Val Ile
Asn Asp Val Leu
Asn Glu Val Val
Asn Ile Asp Val
Asn Ile Val Asp
Asn Lys Ala Gln
Asn Lys Gln Ala
Asn Leu Asp Val
Asn Leu Val Asp
Asn Gln Ala Lys
Asn Gln Lys Ala
Asn Val Asp Ile
Asn Val Asp Leu
Asn Val Glu Val
Asn Val Ile Asp
Asn Val Leu Asp
Asn Val Val Glu
Pro Asp Lys Thr
Pro Asp Thr Lys
Pro Glu Lys Ser
Pro Glu Ser Lys
Pro Gly Met Arg
Pro Gly Arg Met
Pro Lys Asp Thr
Pro Lys Glu Ser
Pro Lys Ser Glu
Pro Lys Thr Asp
Pro Leu Lys Cys
Pro Met Gly Arg
Pro Met Arg Gly
Pro Arg Gly Met
Pro Arg Met Gly
Pro Arg Ser Thr
Pro Arg Thr Ser
Pro Ser Glu Lys
Pro Ser Lys Glu
Pro Ser Arg Thr
Pro Ser Thr Arg
Pro Thr Asp Lys
Pro Thr Lys Asp
Pro Thr Arg Ser
Pro Thr Ser Arg
Gln Ala Glu Ile
Gln Ala Glu Leu
Gln Ala Ile Glu
Gln Ala Lys Asn
Gln Ala Leu Glu
Gln Ala Asn Lys
Gln Asp Val Val
Gln Glu Ala Ile
Gln Glu Ala Leu
Gln Glu Ile Ala
Gln Glu Leu Ala
Gln Gly Lys Gln
Gln Gly Gln Lys
Gln Ile Ala Glu
Gln Ile Glu Ala
Gln Lys Ala Asn
Gln Lys Gly Gln
Gln Lys Asn Ala
Gln Lys Gln Gly
Gln Leu Ala Glu
Gln Leu Glu Ala
Gln Asn Ala Lys
Gln Asn Lys Ala
Gln Gln Gly Lys
Gln Gln Lys Gly
Gln Val Asp Val
Gln Val Val Asp
Arg Ala Asp Val
Arg Ala Val Asp
Arg Asp Ala Val
Arg Asp Gly Ile
Arg Asp Gly Leu
Arg Asp Ile Gly
Arg Asp Leu Gly
Arg Asp Val Ala
Arg Glu Gly Val
Arg Glu Val Gly
Arg Gly Asp Ile
Arg Gly Asp Leu
Arg Gly Glu Val
Arg Gly Ile Asp
Arg Gly Leu Asp
Arg Gly Met Pro
Arg Gly Pro Met
Arg Gly Val Glu
Arg Ile Asp Gly
Arg Ile Gly Asp
Arg Leu Asp Gly
Arg Leu Gly Asp
Arg Met Gly Pro
Arg Met Pro Gly
Arg Pro Gly Met
Arg Pro Met Gly
Arg Pro Ser Thr
Arg Pro Thr Ser
Arg Ser Pro Thr
Arg Ser Thr Pro
Arg Thr Pro Ser
Arg Thr Ser Pro
Arg Val Ala Asp
Arg Val Asp Ala
Arg Val Glu Gly
Arg Val Gly Glu
Ser Glu Lys Pro
Ser Glu Pro Lys
Ser Lys Glu Pro
Ser Lys Pro Glu
Ser Pro Glu Lys
Ser Pro Lys Glu
Ser Pro Arg Thr
Ser Pro Thr Arg
Ser Arg Pro Thr
Ser Arg Thr Pro
Ser Thr Pro Arg
Ser Thr Arg Pro
Thr Asp Lys Pro
Thr Asp Pro Lys
Thr Lys Asp Pro
Thr Lys Pro Asp
Thr Pro Asp Lys
Thr Pro Lys Asp
Thr Pro Arg Ser
Thr Pro Ser Arg
Thr Arg Pro Ser
Thr Arg Ser Pro
Thr Ser Pro Arg
Thr Ser Arg Pro
Val Ala Asp Arg
Val Ala Arg Asp
Val Asp Ala Arg
Val Asp Ile Asn
Val Asp Leu Asn
Val Asp Asn Ile
Val Asp Asn Leu
Val Asp Gln Val
Val Asp Arg Ala
Val Asp Val Gln
Val Glu Gly Arg
Val Glu Asn Val
Val Glu Arg Gly
Val Glu Val Asn
Val Gly Glu Arg
Val Gly Arg Glu
Val Gly Val Trp
Val Gly Trp Val
Val Ile Asp Asn
Val Ile Asn Asp
Val Leu Asp Asn
Val Leu Asn Asp
Val Asn Asp Ile
Val Asn Asp Leu
Val Asn Glu Val
Val Asn Ile Asp
Val Asn Leu Asp
Val Asn Val Glu
Val Gln Asp Val
Val Gln Val Asp
Val Arg Ala Asp
Val Arg Asp Ala
Val Arg Glu Gly
Val Arg Gly Glu
Val Val Asp Gln
Val Val Glu Asn
Val Val Gly Trp
Val Val Asn Glu
Val Val Gln Asp
Val Val Trp Gly
Val Trp Gly Val
Val Trp Val Gly
Trp Ala Ala Ile
Trp Ala Ala Leu
Trp Ala Ile Ala
Trp Ala Leu Ala
Trp Gly Val Val
Trp Ile Ala Ala
Trp Leu Ala Ala
Trp Val Gly Val
Trp Val Val Gly
octyl-2-acetamido-3,4,6-tri-o-acetyl-2-deoxy-beta-d-glucopyranoside
2-[(2S,3S)-1-[tert-butyl(dimethyl)silyl]-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxoazetidin-2-yl]-2-methylpropanedioic acid
Erk5-IN-1
ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM.
(2E)-10-{[3,6-dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy}dec-2-enoic acid
9R-(3R-hydroxy-5R-O-(1H-indol-3-ylcarbonyl)-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-2E-decenoic acid
4-{4-[2-(1A,7A-Dimethyl-4-oxy-octahydro-1-oxa-4-aza-cyclopropa[A]naphthalen-4-YL)-acetylamino]-phenylcarbamoyl}-butyric acid
Trifarotene
D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AD - Retinoids for topical use in acne C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D003879 - Dermatologic Agents
Tert-butyl 4-[(4-amino-3-quinolin-3-ylpyrazolo[3,4-d]pyrimidin-1-yl)methyl]piperidine-1-carboxylate
Panax ginseng Tetrapeptide
Constituent of Panax ginseng (ginseng). Panax ginseng Tetrapeptide is found in tea.
(2S)-N-[(4S,4aR,6S,8S,8aR)-6-(hydroxymethyl)-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetamide
2,5-Dihydroxy-1-octadec-9-enoyloxypyrrole-3-sulfonic acid
N-[(1S,2R,3E,7S,9E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide
2-{[3-cyano-4-(methoxymethyl)-6-methyl-2-pyridinyl]oxy}-N-{[1-(2,6-dimethylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]methylene}acetohydrazide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[(2S,3R,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[(2S,3S)-4-[[(2R)-1-hydroxypropan-2-yl]-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-1,2-oxazol-4-yl)-3-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-1,2-oxazol-4-yl)-3-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[(2R,3R,6R)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6R)-6-[2-[4-(1-hydroxycyclopentyl)triazol-1-yl]ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2-methoxyphenyl)urea
N-[(2R,3S)-4-[[(2S)-1-hydroxypropan-2-yl]-[[4-(trifluoromethyl)phenyl]carbamoyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
N-[(2R,3S)-4-[[(2R)-1-hydroxypropan-2-yl]-[[4-(trifluoromethyl)phenyl]carbamoyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3,3,3-trifluoropropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3,3,3-trifluoropropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3,3,3-trifluoropropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
1-[(2S,3R,6R)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[(2S,3R)-4-[[(2R)-1-hydroxypropan-2-yl]-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
N-[(2S,3S)-4-[[(2S)-1-hydroxypropan-2-yl]-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3,3,3-trifluoropropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3,3,3-trifluoropropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3,3,3-trifluoropropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
1-[(2R,3S,6R)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3S,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[(2R,3R)-4-[[(2S)-1-hydroxypropan-2-yl]-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
N-[(2S,3R)-4-[[(2S)-1-hydroxypropan-2-yl]-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-methoxy-3-methylbutyl]-N-methylcyclopropanecarboxamide
Mutant IDH1-IN-2
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay. Target: Mutant IDH1 Mutant IDH1-IN-2 has a neomorphic activity and in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer. More bioactivity information in Patent WO 2013046136A1 (Example 224).